

## **OPTICEPT ANNOUNCES OUTCOME IN THE EXERCISE OF WARRANTS OF SERIES TO5**

OptiCept Technologies AB (publ) ("OptiCept" or the "Company") today announces the outcome of the exercise of warrants of series TO5, which were issued in connection with the Company's rights issue of units during the fourth quarter of 2022. In total, 1,275,683 warrants of series TO5 were exercised, corresponding to approximately 92.4 percent of the total number of outstanding warrants of series TO5, for subscription of 1,275,683 shares at a subscription price of SEK 5.64 per share. OptiCept will receive approximately SEK 7.2 million before issuing costs through the exercise of the warrants of series TO5.

### **Background**

The subscription period for exercise of the warrants of series TO5 took place during the period from and including 19 May 2023, up to and including 1 June 2023. The subscription price per share for exercising the warrants of series TO5 was set to SEK 5.64.

In total, 1,275,683 warrants of series TO5 were exercised for subscription of 1,275,683 shares, meaning that approximately 92.4 percent of all outstanding warrants of series TO5 were exercised for subscription of shares.

Shares that have been subscribed and paid for will be registered on the subscriber's securities depository as interim shares (IA) until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into shares in OptiCept.

### **Number of shares, share capital and dilution**

Through the exercise of the warrants of series TO5, the number of shares in OptiCept increases by 1,275,683 shares, from 29,567,582 shares to a total of 30,843,265 shares. The share capital will increase by SEK 114,811.47, from SEK 2,661,082.38 to SEK 2,775,893.85.

For existing shareholders who did not exercise any warrants of series TO5, the dilution amounts to approximately 4.1 percent of the number of shares and votes in the Company.

### **Advisers**

Pareto Securities AB acts as Sole Manager and Bookrunner, and Moll Wendén Advokatbyrå AB is legal adviser to the Company in connection with the exercise of warrants.

## Contacts

---

For further information, please contact:

Thomas Lundqvist, CEO  
+46 73 268 05 70  
Thomas.Lundqvist@opticept.se

## About Us

---

OptiCept Technologies AB (publ) provides the food and plant industry with technological solutions that contribute to a more sustainable world and enable climate-smart economic growth. OptiCept optimizes biological processes - Increased extraction from raw material, extended shelf life, reduced waste, and improved quality (taste, aroma, color, nutritional content) of the final product.

The positive effects of technology increase efficiency for our customers, better products for the consumers, and minimal impact on our environment. Through patented technology in PEF (pulsed electric field) and VI (Vacuum Infusion), the technology opens up new business opportunities for the food and plant industry worldwide. OptiCept's vision is to contribute to a sustainable world by offering efficient green cutting-edge technology that is easy to use in the areas of FoodTech and PlantTech.

The company is located in Lund and the share is traded on the Nasdaq First North Growth Market. Erik Penser Bank is a Certified Adviser and is available at 08-463 80 00 or [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se).

For further information visit:  
[OptiCept Technologies Official Website](#)

*This information is information that OptiCept Technologies is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-06-02 14:20 CEST.*

## Attachments

---

**[OptiCept announces outcome in the exercise of warrants of series T05](#)**